Abstract: Ji Suyun, Chen Yongfeng, Gong Xiao, Gu Mei, Wang Yu, Yuan Liyan, Yang Bin Department of Dermatology, Guangdong Provincial Dermatology Hospital, Guangzhou 510091, China （Ji SY, Chen YF, Gu M, Wang Y, Yuan LY, Yang B）; School of Public Health, Guangdong Pharmaceutical University, Guangzhou 510006, China （Gong X） Corresponding author: Yang Bin, Email: binyang101@163.com 【Abstract】 Objective To investigate changes in serum levels of antinuclear antibody （ANA）, anti-double-stranded DNA （dsDNA） antibody and anti-extractable nuclear antigen （ENA） antibody before and after anti-tumor necrosis factor-α （TNF-α） therapy in psoriatic patients. Methods Clinical data obtained from 32 patients with psoriasis were analyzed retrospectively. Of the 32 patients, 13 received intravenous injection of 5 mg/Kg infliximab at week 0, 2, 6 for 3 sessions, then once every 8 weeks （infliximab group）, while other 19 received subcutaneous injection of 25 mg etanercept twice every week （etanercept group）. The treatments in the 2 groups both lasted more than 3 months. Serum levels of ANA, anti-dsDNA antibody and anti-ENA antibody and changes of clinical symptoms were detected and observed respectively before each treatment in the infliximab group, as well as every 3 - 6 months in the etanercept group. The 75% reduction in psoriasis area and severity index （PASI75） and disease activity score of 28 joints （DAS28） were used to evaluate clinical efficacy. Serum levels of ANA, anti-dsDNA antibody and anti-ENA antibody were measured by indirect immunofluorescence （IIF） assay, Western blot analysis combined with enzyme-linked immunosorbent assay （ELISA）, and Western blot analysis, respectively. Results After 3-month treatment, the 32 patients achieved clinical remission to different extents. Of 32 patients receiving anti-TNF-α therapy, 7 （21.9%） developed new autoantibodies. Concretely speaking, 4 patients in the infliximab group developed autoantibodies in 8.3 ± 5.1 months, including 3 cases positive for ANA and 3 for anti-ENA antibody. Three patients in the etanercept group developed autoantibodies in 9.0 ± 3.0 months, including 3 cases positive for ANA and 1 for anti-ENA antibody. Conclusion Partial patients with psoriasis may develop autoantibodies after anti-TNF-α therapy.